Laurence Matthew Skelton - 20 Jan 2026 Form 3 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
Chief Commercial Officer
Signature
/s/ Joseph Young, attorney-in-fact
Issuer symbol
VERA
Transactions as of
20 Jan 2026
Net transactions value
$0
Form type
3
Filing time
30 Jan 2026, 16:05:05 UTC
Next filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Skelton Laurence Matthew Chief Commercial Officer C/O VERA THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE /s/ Joseph Young, attorney-in-fact 30 Jan 2026 0002108080

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VERA Class A Common Stock 30,000 20 Jan 2026 Direct F1
holding VERA Class A Common Stock 15,800 20 Jan 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERA Stock Option (right to buy) 20 Jan 2026 Class A Common Stock 60,000 $41.75 Direct F3
holding VERA Stock Option (right to buy) 20 Jan 2026 Class A Common Stock 31,500 $29.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs"). One-fourth of the RSUs vested on November 20, 2025, and the remaining three-fourths will vest in equal installments on each of November 20, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date.
F2 Represents the number of shares of Class A Common Stock underlying the RSUs. One-fourth of the RSUs vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date.
F3 One-third of the shares subject to the stock option vested through January 30, 2026, and 1/48 of the shares vest on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.
F4 11/48 of the shares subject to the stock option vested through January 18, 2026 and 1/48 of the shares vest on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney No securities are beneficially owned.